Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10251711 | 1.00 | HSD17B10 (0.44) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL10000706 | 1.00 | HSD17B10 (0.44) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL12747962 | 1.00 | HSD17B10 (0.44) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL12747968 | 0.94 | HSD17B10 (0.40) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL12747959 | 0.94 | HSD17B10 (0.40) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL12438440 | 0.91 | HSD17B10 (0.38) | HSD17B10S1PR1 | |
| SCHEMBL19342996 | 0.91 | HSD17B10 (0.38) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL12018091 | 0.90 | HSD17B10 (0.37) | HSD17B10SLC6A9 | |
| SCHEMBL19598843 | 0.90 | CHRM5 (0.38) | HSD17B10SLC6A9 | |
| SCHEMBL15143766 | 0.90 | ALDH1A1 (0.39) | HSD17B10SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9764048-B2 | Targeted molecular imaging probe and method for in vivo molecular imaging | SHEN BAOZHONG (CN) | 2017-09-19 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | SNU R&DB FOUNDATION (KR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | GJB2, GJA1, GAP43 | HSD17B10 3433/4885SLC6A9 3051/4885S1PR1 2121/4885 |
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | DDC, AAAS, DNPEP | HSD17B10 3217/4885SLC6A9 3908/4885S1PR1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.